+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cardiac Biomarkers Testing Market by Type, Application and Location of Testing: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4828599
  • Report
  • Region: Global
  • 256 pages
  • Allied Analytics LLP
1 of 4
The global cardiac biomarker market generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4%. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state as well as for diagnostic and prognostic purposes associated with heart. The prevention of cardiac diseases by monitoring heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS), and others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA, and others. The global cardiac biomarkers testing market has witnessed a greater demand over the past five to six years.

The ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain acts as a key factor that boosts the growth of the global cardiac market. In addition, promising features such as high accuracy, quick outcomes, and economic pricing of cardiac point of care (POC) testing drive the market growth. To keep the momentum of cardiac marker tests, key manufacturers offer customized solutions, thus propelling the growth of the market. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions serves as the key opportunity for market expansion. However, limited specificity in some cases and side effects such as skeletal muscle injury restrain the growth of the cardiac biomarkers testing market.

The global cardiac biomarker market is segmented based on type, application, location of testing, and region. By type, the market is fragmented into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and others. Depending on application, it is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, it is bifurcated into point of care testing and laboratory testing. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report highlights the market dynamics to understand the global cardiac biomarker market and capitalize on the prevailing opportunities.
Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.

KEY MARKET SEGMENTS
  • By Type
o Myocardial Muscle Creatine Kinase (CK-MB)
o Troponins (T and I)
o Myoglobin
o Brain Natriuretic Peptide (BNPs) or NT-proBNP
o Ischemia-modified Albumin (IMA)
o Others
  • By Application
o Myocardial Infarction
o Congestive Heart Failure
o Acute Coronary Syndrome
o Atherosclerosis
o Others
  • By Location of Testing
o Point of Care Testing
o Laboratory Testing
  • By Region
o North America
  • U.S.
  • Canada
  • Mexico
o Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
o Asia-Pacific
  • Australia
  • Japan
  • India
  • China
  • Rest of Asia-Pacific
o LAMEA
  • Latin America
  • Middle East
  • Africa
KEY MARKET PLAYERS
  • Roche Diagnostics
  • Abbott Laboratories
  • Siemens Healthcare
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • BioMerieux
  • PerkinElmer Inc.
  • Tosoh Corporation
  • Danaher Corporation
  • Thermo Fisher Scientific
The other players in the value chain include (profiles not included in the report):
  • Randox Laboratories
  • Johnson and Johnson
  • Olympus Corporation
  • BG Medicines
  • ACS Biomarker B.V.
  • Cavadis Biomedical.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings
2.1.1. Top impacting factors
2.1.2. Top investment pockets
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Biomarker diagnosis vs. conventional diagnosis
3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers
3.3.1. Early diagnosis
3.3.2. Tissue specific diagnosis
3.3.3. Reduce clinical trials
3.3.4. Consistent output
3.4. Key trends impacting the Cardiac biomarker testing market
3.4.1. Development of high sensitive biomarkers for risk stratification
3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3. Increasing demand for point of care cardiac diagnostics
3.5. Parent Market Overview
3.6. Key Forces Shaping Cardiac biomarker testing market
3.6.1. High bargaining power of suppliers
3.6.2. Low bargaining power of buyers
3.6.3. Low threat of new entrants
3.6.4. Low threat of substitutes
3.6.5. High intensity of rivalry
3.7. Value chain analysis
3.8. Pricing Analysis
3.8.1. Pricing Analysis, By Region, 2018 & 2025
3.9. Market evolution/Industry roadmap
3.10. Government regulations
3.11. Reimbursement issues
3.12. Patent Analysis
3.12.1. By Region (2016-2018)
3.12.2. By Applicant
3.13. Market share analysis
3.14. Case Studies
3.14.1. Case Study
3.15. Market dynamics
3.15.1. Drivers
3.15.1.1. Increasing prevalence of cardiovascular diseases
3.15.1.2. Cost effective
3.15.1.3. Non-invasive
3.15.1.4. Accuracy prediction
3.15.1.5. Technological advancements using cardiac biomarkers combinations
3.15.1.6. Increasing point of care (POC) testing
3.15.2. Restraints
3.15.2.1. Government Regulation
3.15.2.2. Conformation in result
3.15.2.3. Complex process
3.15.3. Opportunities
3.15.3.1. Personalized medicine
3.15.3.2. Point of care (POCT) testing using cardiac biomarkers

CHAPTER 4: CARDIAC BIOMARKER TESTING MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Creatine kinase (CK-MB)
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Troponins
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Myoglobin
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Natriuretic peptides (BNP and NT-proBNP)
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Ischemia modified albumin
4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country

CHAPTER 5: CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Myocardial infarction
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Congestive heart failure
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Acute coronary syndrome
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Atherosclerosis
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other applications
5.6.1. Market size and forecast
5.6.2. Market analysis, by country

CHAPTER 6: CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING
6.1. Overview
6.1.1. Market size and forecast
6.2. Point of care testing
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Laboratory testing
6.3.1. Market size and forecast
6.3.2. Market analysis, by country

CHAPTER 7: CARDIAC BIOMARKER TESTING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. North America market size and forecast, by type
7.2.3. North America market size and forecast, by application
7.2.4. North America market size and forecast, by location of testing
7.2.5. North America market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. U.S. market size and forecast, by type
7.2.5.1.2. U.S. market size and forecast, by application
7.2.5.1.3. U.S. market size and forecast, by location of testing
7.2.5.2. Canada
7.2.5.2.1. Canada market size and forecast, by type
7.2.5.2.2. Canada market size and forecast, by application
7.2.5.2.3. Canada market size and forecast, by location of testing
7.2.5.3. Mexico
7.2.5.3.1. Mexico market size and forecast, by type
7.2.5.3.2. Mexico market size and forecast, by application
7.2.5.3.3. Mexico market size and forecast, by location of testing
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Europe market size and forecast, by type
7.3.3. Europe market size and forecast, by application
7.3.4. Europe market size and forecast, by location of testing
7.3.5. Europe market size and forecast, by country
7.3.5.1. UK
7.3.5.1.1. UK market size and forecast, by type
7.3.5.1.2. UK market size and forecast, by application
7.3.5.1.3. UK market size and forecast, by location of testing
7.3.5.2. France
7.3.5.2.1. France market size and forecast, by type
7.3.5.2.2. France market size and forecast, by application
7.3.5.2.3. France market size and forecast, by location of testing
7.3.5.3. Germany
7.3.5.3.1. Germany market size and forecast, by type
7.3.5.3.2. Germany market size and forecast, by application
7.3.5.3.3. Germany market size and forecast, by location of testing
7.3.5.4. Rest of Europe
7.3.5.4.1. Rest of Europe market size and forecast, by type
7.3.5.4.2. Rest of Europe market size and forecast, by application
7.3.5.4.3. Rest of Europe market size and forecast, by location of testing
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by type
7.4.3. Asia-Pacific market size and forecast, by application
7.4.4. Asia-Pacific market size and forecast, by location of testing
7.4.5. Asia-Pacific market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. China market size and forecast, by type
7.4.5.1.2. China market size and forecast, by application
7.4.5.1.3. China market size and forecast, by location of testing
7.4.5.2. India
7.4.5.2.1. India market size and forecast, by type
7.4.5.2.2. India market size and forecast, by application
7.4.5.2.3. India market size and forecast, by location of testing
7.4.5.3. Australia
7.4.5.3.1. Australia market size and forecast, by type
7.4.5.3.2. Australia market size and forecast, by application
7.4.5.3.3. Australia market size and forecast, by location of testing
7.4.5.4. Japan
7.4.5.4.1. Japan market size and forecast, by type
7.4.5.4.2. Japan market size and forecast, by application
7.4.5.4.3. Japan market size and forecast, by location of testing
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Rest of Asia-Pacific market size and forecast, by type
7.4.5.5.2. Rest of Asia-Pacific market size and forecast, by application
7.4.5.5.3. Rest of Asia-Pacific market size and forecast, by location of testing
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. LAMEA market size and forecast, by type
7.5.3. LAMEA market size and forecast, by application
7.5.4. LAMEA market size and forecast, by location of testing
7.5.5. LAMEA market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Latin America market size and forecast, by type
7.5.5.1.2. Latin America market size and forecast, by application
7.5.5.1.3. Latin America market size and forecast, by location of testing
7.5.5.2. Middle East
7.5.5.2.1. Middle East market size and forecast, by type
7.5.5.2.2. Middle East market size and forecast, by application
7.5.5.2.3. Middle East market size and forecast, by location of testing
7.5.5.3. Africa
7.5.5.3.1. Africa market size and forecast, by type
7.5.5.3.2. Africa market size and forecast, by application
7.5.5.3.3. Africa market size and forecast, by location of testing

CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Becton, Dickinson and Company
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BioMerieux
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.4. Bio-Rad Laboratories, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. Danaher Corporation
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. F. HOFFMANN-LA ROCHE LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.7. Siemens AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. Thermo Fisher Scientific, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.9. PerkinElmer Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.10. Tosoh Corporation
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled,'Cardiac Biomarkers Testing Market by Type, Application, and Location of Testing: Global Opportunity Analysis and Industry Forecast, 2019 - 2026,'The global cardiac biomarkers testing market size generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4% from 2019 to 2026. The cardiac troponins segment, both T and I, forefronts among all other cardiac biomarker types, holding the largest share due to its strong performance, as cardiac troponins are the most sensitive and specific biomarkers for subsequent events of myocardium injury.

The global cardiac biomarkers testing market has witnessed significant growth in the past few years, and is anticipated to continue to grow at a consistent pace, due to high prevalence of cardiac diseases that widely remain undiagnosed. Large number of cardiac biomarkers in pipeline, augmented patient awareness toward the importance of early detection of cardiovascular diseases, and opportunities in untapped countries such as India, China, and other Asia-Pacific countries are the key factors that contribute toward the growth of the market. In addition, introduction of novel cardiac biomarkers for point of care (POC) testing and facilitating quick results for chronic patients serve as opportunistic approaches to drive the market growth. However, premium pricing of approved and novel single used cardiac biomarkers and uncertain government regulation regarding the approval for biomarker tests and assays are expected to hinder the market growth during the analysis period.

Presence of large undiagnosed patient population, rise in incidence of cardiovascular diseases (CVDs), rapid urbanization, increase in disposable income, improved government funding toward healthcare, and surge in awareness about cardiac events, i.e., quick checkups after the onset of chest pain are the prime reasons responsible for the market growth in North America. Furthermore, the market growth is driven by novel progress in the treatments with improved overall survival benefits using multi-assay biomarkers. The survival benefit would be influential in governing the peak sales and market penetration of novel approved cardiac biomarker-based devices.

Based on cardiac biomarker type, the market is segmented into creatine kinase (CK-MB), troponins T and I, myoglobin, BNPs, IMA, and others. The IMA segment is expected to grow at high CAGR, as these biomarkers improve the sensitivity and negative predictive value for the diagnosis of myocardial ischemia when used in combination with standard cardiac biomarkers.

The applications covered in the study include myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The congestive heart failure segment is expected to register the highest growth rate, owing to increased demand for biomarker tests for early detection of heart failure.

North America led the global market in 2018, due to high demand for cardiac testing, increase in prevalence rate of CVD, and rise in awareness toward cardiac diagnostics solutions. Moreover, intensive efforts taken by government and research institutes to deal with critical cardiac diseases and increase in R&D activities related to cardiac biomarkers are expected to boost the market growth in North America.

Key Findings of the Cardiac Biomarkers Testing Market:

By type, the troponin segment is projected to dominate the market during the forecast period.
The myocardial infarction segment is expected to grow more than twofold during the forecast period.
Laboratory testing market is expected to garner XX of the overall market revenue by 2026
Based on location of testing segment, the point of care cardiac biomarker testing segment is projected to grow at a CAGR of XX% throughout the forecast period.
Asia-Pacific region holds immense future market potential as there is a higher count of undiagnosed Cardiac patients diagnosed precisely

The report provides a comprehensive analysis of the key players operating in the global cardiac biomarkers testing market , namely, Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, PerkinElmer Inc., Tosoh Corporation, Danaher Corporation, and Thermo Fisher Scientific.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll